技术指标
指标
数值
方向
MACD(12,26,9)
-0.181
中性
RSI(14)
26.418
卖出
STOCH(KDJ)(9,3,3)
14.238
超卖
ATR(14)
0.214
低波动
CCI(14)
-317.841
超卖
Williams %R
92.683
超卖
TRIX(12,20)
0.021
卖出
StochRSI(14)
0.000
超卖
搜索
Cerus Corp
CERS添加自选
2.150USD
-0.740-25.61%
收盘 07-31 16:00（美东）报价延迟15分钟
433.28M总市值
亏损市盈率 TTM
关键数据
2.430今开
2.460最高
8.33M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
4.16%换手率
2.890昨收
2.060最低
13.48M成交额
亏损市盈率静
6.38市净率
0.00%股息率 TTM
-4.45%ROA
3.15052周最高
2.70量比
-20.92M净利润
200.32M总股本
-0.0492每股收益TTM
1.73Beta
-15.52%ROE
1.15052周最低
13.84%振幅
75.71%毛利率
433.28M总市值
-3.00回报/风险
3.96%风险率
TradingKey Cerus Corp股票评分
单位: USD 更新时间: 2026-07-31操作建议
Cerus Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名44/199位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cerus Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Cerus Corp亮点
亮点风险
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
业绩高增长
公司营业收入稳步增长，连续3年增长25.16%
估值低估
公司最新PE估值-43.71，处于3年历史低位
机构加仓
最新机构持股147.40M股，环比增加2.95%
凯茜·伍德（木头姐）持仓
明星投资者凯茜·伍德（木头姐）持仓，最新持仓市值12.37M
活跃度降低
近期活跃度降低，过去20天平均换手率0.46
分析师目标
根据
3
位分析师
买入
评级
4.667
目标均价
+117.05%
涨幅空间
Cerus Corp新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
3
位分析师
买入
评级
4.667
目标均价
+117.05%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
109
总数
7
中位数
9
平均值
公司名称
评级分布
分析师数
Cerus Corp
CERS
3
美敦力
MDT
34
史赛克
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
雅培
ABT
29
1
2
3
...
22
技术指标
移动平均线
指标
数值
方向
MA5
2.780
卖出
MA10
2.899
卖出
MA20
3.029
卖出
MA50
2.855
卖出
MA100
2.455
卖出
MA200
2.233
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cerus Corp简介
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
公司代码CERS
公司Cerus Corp
CEOGreenman (William M)
网址https://www.cerus.com/
公司股东
相关品种
-1.72%
-0.43%
+0.12%
-0.59%
-0.74%
-6.42%
+0.10%
-0.36%
+1.75%
-0.14%
-2.99%
+1.58%
-0.29%
+0.41%
-1.02%
+0.13%
+0.05%
-0.80%
-0.24%
-0.70%热门品种
常见问题
Cerus Corp(CERS)的当前股价是多少？
Cerus Corp(CERS)的当前股价是 2.15。
Cerus Corp的股票代码是什么？
Cerus Corp的股票代码是CERS。
Cerus Corp股票的52周最高点是多少？
Cerus Corp股票的52周最高点是3.15。
Cerus Corp股票的52周最低点是多少？
Cerus Corp股票的52周最低点是1.15。
Cerus Corp的市值是多少？
Cerus Corp的市值是433.28M。
现在Cerus Corp(CERS)的股票是买入、持有还是卖出？
根据分析师评级，Cerus Corp(CERS)的总体评级为买入，目标价格为4.67。
Cerus Corp(CERS)股票的每股收益（EPS TTM）是多少
Cerus Corp(CERS)股票的每股收益（EPS TTM）是-0.08。